| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| UTHR has a current Overall Rating of B (Positive). | 7 |
$25 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for UTHR. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| UTHR: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | UNITED THERAPEUTICS CORPORATION (UTHR=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of UNITED THERAPEUTICS CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P Super 1500 Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P MidCap Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for UTHR | 13 |
$25 |
1.48% Nasdaq 
Research Reports
